A controlled comparative study of chlorprothixene vs. haloperidol in chronic schizophrenia.
Neurochemical distinctions have been made between neuroleptic drugs that affect D-1 receptors as well as D-2 receptors, compared with those neuroleptic drugs that affect only D-2 receptors. However, a controlled double-blind study of haloperidol vs. chlorprothixene in schizophrenic patients found no significant differences.
Fux
M
M
Beersheva Mental Health Center-Division of Psychiatry, Ben Gurion University, School of Medicine, Israel.
Belmaker
R H
RH
D000328:Adult; D001921:Brain / Q000187:drug effects; D002749:Chlorprothixene / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D005260:Female; D006220:Haloperidol / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011954:Receptors, Dopamine / Q000187:drug effects; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology
D011954:Receptors, Dopamine; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D002749:Chlorprothixene; D006220:Haloperidol